Antiangiogenic Therapies: Going beyond Their Limits
L. Moserle, G. Jiménez-Valerio, and O. Casanovas

mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1

Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity

MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

Climbing RAS, the Everest of Oncogenes
M. Russo, F. Di Nicolantonio, and A. Bardelli

miR-30c-2-3p and miR-30a-3p: New Pieces of the Jigsaw Puzzle in HIF2α Regulation
H. Moch and M. Lukamowicz-Rajska

Faulty ECM Signaling Facilitates Autoimmune Lymphomagenesis
R.A. Brekken

Towards a Unified Model of RAF Inhibitor Resistance
D.B. Solit and N. Rosen

In Focus
Towards a Unified Model of RAF Inhibitor Resistance
D.B. Solit and N. Rosen

Précis: mTORC inhibitors decrease MCL-1 translation and cooperate with BCL-2/BCL-XL inhibitors to induce apoptosis and growth arrest in KRAS- and BRAF-mutant colorectal cancer.
See commentary, p. 19

Précis: Repression of specific miRNAs antagonizes the tumor-suppressive activity of HIF1α in ccRCC tumors by augmenting expression of the oncoprotein HIF2α.
See commentary, p. 22

Précis: Whole-exome and transcriptome sequencing of dabrafenib- and trametinib-resistant melanomas identifies putative mechanisms of acquired resistance to combined RAF/MEK inhibition.
See commentary, p. 27

In The Spotlight
Climbing RAS, the Everest of Oncogenes
M. Russo, F. Di Nicolantonio, and A. Bardelli

miR-30c-2-3p and miR-30a-3p: New Pieces of the Jigsaw Puzzle in HIF2α Regulation
H. Moch and M. Lukamowicz-Rajska

Faulty ECM Signaling Facilitates Autoimmune Lymphomagenesis
R.A. Brekken

Towards a Unified Model of RAF Inhibitor Resistance
D.B. Solit and N. Rosen

For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.
Using data from a high-throughput drug screen, Faber and colleagues found that AZD8055, an inhibitor of mTOR complexes 1 and 2 (TORC1/2), cooperated with the BCL-2/BCL-XL inhibitor ABT-263 to induce cell-cycle arrest and apoptosis specifically in KRAS- and BRAF-mutant colorectal cancer cell lines. This genotype selectivity was mediated by suppression of the antiapoptotic protein MCL-1 and disruption of BIM–MCL-1 complexes in response to TORC1/2 inhibition, which sensitized KRAS-mutant cells to ABT-263 and triggered apoptosis. Furthermore, dual treatment with ABT-263 and AZD8055 preferentially induced tumor regression in KRAS-mutant colorectal cancer xenograft and genetically engineered mouse models. These results support further clinical development of this therapeutic combination for patients with KRAS- and BRAF-mutant colorectal cancer. For details, please see the article by Faber and colleagues on page 42.

For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org. Online-only News stories include the following:

- NCI Issues Omics Checklist for Tests
- Obinutuzumab Breaks through to FDA Approval
- ICR Expands CanSAR Drug Discovery Platform
- ASCO Forges Ahead with CancerLinQ
- HPV Vaccine Works against Nine Viral Types
- Ibrutinib Approved for Mantle Cell Lymphoma

AC icon indicates Author Choice
For more information please visit http://www.aacrjournals.org